MicroRNAs as biomarkers in molecular diagnosis of refractory epilepsy by unknown
REVIEW Open Access
MicroRNAs as biomarkers in molecular
diagnosis of refractory epilepsy
Xiaofeng Wang1,2,4†, Hang Yin3†, Alyson M. Rich5,6,7, Yuqiang Sun2, Zeshi Tan2, Xiaodong Luo2, Ningwei Che2,
Minghai Wei2* and Jian Yin2,4*
Abstract
MicroRNA (miRNA) is a type of endogenous non-coding RNA that can regulate cell proliferation, differentiation,
invasion, apoptosis and several other biological activities by specially inducing gene silencing, and thereby is
related to development and disease in life course. In recent years, researchers have found that miRNAs are closely
related with refractory epilepsy. MiRNAs can intervene in the modification of mRNAs, the synthesis of proteins and
some the connectivity of signal pathways in pathogenesis of epilepsy. Furthermore, some miRNAs in neurons are of
great importance in neuronal differentiation. Therefore, miRNA may play a very important role in the occurrence,
development and episodes of refractory epilepsy. These discoveries can provide a new direction for the research of
pathogenesis, diagnostic methods and therapeutic approach of refractory epilepsy. Although research about miRNA
and intractable epilepsy has progressed, more remains to be done before miRNA can be used in clinical diagnosis
and treatment strategies. This paper focuses on the research progress of molecular diagnosis about miRNA in
intractable epilepsy.
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Background
Epilepsy is a chronic neurologic disorder characterized
by recurring abnormal electricity activity in brain, which
is estimated to afflict about 65 million individuals world-
wide [1]. Approximately 10 % of the publics have at least
one seizure during their lifetime and among them about
30 % will develop epilepsy, suffering substantial deleteri-
ous influence on their health due to long-term use of
drugs [2]. Nowadays it lacks a complete understanding of
the epileptogenic process but it is thought to involve neur-
onal death or dysfunction, neurogenesis and others [2].
Many researchs now support miRNAs as a critical layer of
gene expression regulation in epilepsy, which provides
new putative targets for the control of seizures, seizure-
induced damage and as potential biomarkers of epilepto-
genesis. miRNA is detected in many biofluids, including
serum and CSF and it appears to be very stable [3, 4].
Current strategies to fight epilepsy focus on arresting
epileptogenesis induced by brain trauma and other dis-
eases through treatment of anti-epileptic drugs [3]. Sub-
stantial research has focused on the involvement of
microRNAs in epilepsy, including screening the aberrant
expression of microRNAs and searching their target
genes. The isolation of miRNAs’ target genes would en-
able the development of a better understanding of the eti-
ology, and the establishment of diagnostic biomarkers,
and the identification of novel miRNA-based therapeutics.
Drug-resistant epilepsy: definition and prognosis
Globally, the estimated proportion of the general popu-
lation with active epilepsy is about 0.5-1 % and 20–30 %
of those patients will develop a drug-resistant epilepsy
(DRE) [4, 5]. Clinical trials demonstrated that cerebro-
vascular diseases, encephalitis and cortical dysplasia
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function as main causes of DRE. Diseases including
West syndrome, Lennox-Gastaut syndrome and tuber-
ous sclerosis could assist in identifying DRE [6]. More-
over, temporal lobe epilepsy (TLE) represents the most
common syndrome in adults and often develops phar-
macoresistence [7]. TLE frequently develops into DRE as
a result of hippocampal sclerosis (HS) [8–10], inflamma-
tion [11], neurocysticercosis [12], brain insult [13], or
malformations of cortical development [14, 15]. How-
ever, a consensus definition and prognosis for DRE
remained elusive [16, 17]. In 2010, the International
League against epilepsy (ILAE) addressed the need for a
definition, declaring that“Drug resistant epilepsy may be
defined as failure of adequate trials of two tolerated and
appropriately chosen and used AED schedules (whether
as monotherapies or in combination) to achieve sus-
tained seizure freedom” [18]. This proposal provided a
precise definition of DRE but, left forming an efficacious
prognosis method for DRE unexplored to this day. Past
early-identification of DRE is mainly based on clinical
manifestations like the number of seizures [19]. Other
than applying the well-established electroencephalography
(EEG) monitoring, other imaging testsing and clinical
symptoms and signs watching, DRE urgently requires a
set of molecular biomarkers to clarify the early prognosis,
wherein microRNAs play an important role [20–22].
MicroRNA: biogenesis and regulatory mechanisms
miRNA is a non-coding single-stranded RNA molecule
with length of about 20–24 nucleotides and has highly
conservatism, tissue specificity and temporality. It does
not have open reading frame and mainly regulates ex-
pression of gene after transcription [23]. Most miRNA
genes are present in the genome as the form of single
copy, multiple copies or a gene cluster. Each miRNA
can regulate one or more target genes, while several
miRNAs can regulate the same target gene. miRNA reg-
ulates the expression level of proteins in cells through
this complicated network [24]. Essentially, miRNA is a
highly conserved non-coding single-stranded endogen-
ous RNA molecule that plays an important role in the
negative regulation of the target gene expression after
transcription [25].
MicroRNAs in animal experiments of DRE
prognosis
In animal experiments about DRE, researchers mainly
focused on temporal lobe epilepsy and hippocampal
sclerosis by artificially modeling mice or rats. Re-
searchers further compartmentalized subgroups by dis-
tinguishing different time phases of seizures, different
locations and different injury statuses of the brain.
MicroRNAs profiling in different time phases after SE
The detection of abnormal expression of miRNAs in tis-
sue is usually obtained during status epilepticus (SE) and
after induction of SE at 1 day, 1 week or over 2 months.
Distinct expression levels of miRNAs have been discov-
ered at all time points. Thus, researchers considered the
alteration of miRNA levels in interictal periods and
chronic stage to have great diagnostic significance. To
date, over 350 different miRNAs are postulated to
closely correlate with epileptogenesis and epilepsy devel-
opment while only up to 20 % of these miRNAs have
been identified in brain tissues of epilepsy animal models
[26]. Researchers suppose that such heterogeneity may
be the result of the influence exerted by epilepsy-
induced brain tissue damage to miRNA detection, thus
choosing to conduct miRNA profiling in brain tissues
extracted at least 2 months (chronic stage) after epileptic
seizures. Four animal-based studies utilizing gene chips
to identify miRNA expression, respectively conducted by
Song et al. [26] Hu et al. [27] Bot et al. [28] and Gorter
et al. [29], together reported about 25 differentially
expressed miRNAs. Those mentioned in more than one
of the studies include 14 up-regulated miRNAs and 9
down-regulated miRNAs. Up-regulated miRNAs in-
cludes miR-21, miR-23a, miR-23b, miR-24, miR-27a,
miR-27b, miR-34a, miR-126, miR-132, miR-140, miR-
146a, miR-152, miR-210 and miR-212 while down-
regulated miRNAs includes miR-33, miR-138, miR-139,
miR-187, miR-190, miR-218a, miR-301a, miR-551b and
miR-935. Among the up-regulated miRNAs only three
were mentioned in three human experiments, which are
miR-21, miR-132 and miR-146a [30–32]. Of note, miR-
134 is also an important microRNA that is up-regulated
during epilepsy, which is only profiled in one human ex-
periment of Jimenez-Manteos et al. [23].
MicroRNAs profiling in different damage status of brain
Through distinguishing differential damage statuses (in-
cluding intercerebral hemorrhagic injury (H), ischemic
injury (I) and kainate seizures (K)) of rat brains after epi-
leptic seizures in 24 h, Liu et al. [33] identified 91 miR-
NAs in brain (I+:24, H+:17, K+:13; I-:13, H-:12, K-:18)
and 147 miRNAs in blood (I+:10 H+:21 K+:21 I-:65 H-
:20 K-:10) that exhibits abnormal expressions (fold
change > 1.5) in three damage statuses. Among them,
miRNAs that show aberrant expression in mice brain
tissue of all three damage statuses includes up-regulated
miR-542-3p and down-regulated miR-122, miR-155,
miR-362-3p and miR-450-5p. In blood, five up-regulated
miRNAs were clearly documented miR-96, miR-152,
miR-298, miR-333 and miR-505. Seven down-regulated
miRNAs were also found in the blood: being miR-125a-
5p, miR-130b, miR-142-3p, miR-330, miR-342-5p, miR-
347 and miR-685 miRNAs that are both regulated in
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brain and blood include miR-298, miR-503, miR-672,
miR-10a, miR-182 and miR-200b (SI & I+); miR-155,
miR-362-3p, miR-223 and miR-210 (SI & I-); miR-148b,
miR-503, miR-298, miR-423-5p, miR-10a, miR-345-5p
and miR-674 (SH & LB(H)+); miR-10b, miR-203, miR-
362-3p, miR-155, miR-20b-3p and miR-200a (SH &
LB(H)-); miR-298 (K+); miR-155, miR-29c, miR-34b-3p,
miR-98, miR-122, miR-203 and miR-450a (K-). Since
considerable amounts of miRNAs have been successfully
identified, future studies should focus more on the clin-
ical significance of particular miRNAs used as bio-
markers or potential therapeutic targets.
MicroRNAs profiling in different area of brain after SE
Jan et al. [34] have analyzed the miRNA expression in
three brain regions - hippocampal CA1, hippocampal den-
tate gyrus and parahippocampal cortex-correlated with
TLE in rats and obtained tissue after electrically-induced
SE at 1 day, 1 week and 3–4 months. Results revealed that
18, 16 and 7 miRNAs were identified respectively in the
hippocampal CA1 in the aforementioned three time
phases. Among them, miR-21 exhibits high expression in
both tissue obtained in 1 day and 1 week after SE induc-
tion and miR-143, miR-23a, miR-27a showed up-
regulation in tissue obtained after 1 week and 3–4
months. In the hippocampal dentate gyrus, there were 20,
15 and 37 miRNAs respectively detected in the three time
phases. Three miRNAs - miR-132, miR-21, miR-212 - ex-
hibited up-regulation in all three time phases while miR-
142-5p was up-regulated in 1 days and 1 weeks after SE.
miR-146a, miR-212, miR-23a were up-regulated in 1 day
and 3–4 months after SE and miR-223 showed up-
regulation in 1 day and 3–4 months after SE. In the para-
hippocampal cortex, 31, 37 and 22 miRNAs respectively
were profiled in three time phases. miR-21 and miR-223
displayed up-regulation in all three time phases; 12 miR-
NAs (miR-142-5p, miR-294, miR-32, miR-351, miR-3596c,
miR-466b-1, miR-466b-2, miR-466c, miR-466d, miR-675,
miR-758 and miR-883)were up-regulated in 1 day and
1 week after SE samples,; and 6 miRNAs (miR-193, miR-
199a-3p, miR-199a-5p, miR-23a, miR-27a, miR-34a) pre-
sented up-regulation in both 1 week and 3–4 months.
However, extremely few miRNAs were identified in the
hippocampal CA1 and dentate gyrus and not a single
miRNA was identified in all three time phases. In the
parahippocampal cortex, respectively 68, 102 and 7 miR-
NAs were identified in three time phases while only miR-
137 was down-regulated in all three time phases.
Currently no research has focused on the relationship be-
tween miR-137 and intractable epilepsy. Aside from brain
tissue, Jan et al. also profiled miRNAs in plasm and 3 miR-
NAs were detected, being miR-142-5p detected in 1 day
after SE, miR-21-5p in 1 week after SE and miR-146-5p in
3–4 months after SE. No miRNA was detected in two or
three time phases.
Although such substantial miRNAs were identified in
tissue and plasm in different time phases, areas and
damage statuses, few miRNAs show essential clinical sig-
nificance. Blondal et al. [35] assessed 119 miRNAs that
are most commonly found in normal plasm, wherein 9
miRNAs are overlapped with those identified by Jan et
al. in brain tissue and 8 miRNAs plasma (5 tissue + 3
plasm) are overlapped with those detected by Liu et al.
in brain tissue and plasm. These respectively are miR-21,
miR-142-5p, miR-146a, miR-23a, miR-223, miR-32, miR-
199a-3p, miR-199a-5p, miR-27a (Jan et al. Tissue over-
lapped), miR-122, miR-152, miR-505, miR-125a-5p, miR-
142-3p (Liu et al. Tissue overlapped), miR-20b, miR-29c,
miR-122 (Liu et al. Plasm overlapped) The scarcity of
these findings indicates that these miRNAs may have lit-
tle relation with epileptogenesis. However, microRNAs
such as miR-146a are still validated to be highly impli-
cated in epileptogenesis. Thus, whether those 17 micro-
RNAs are involved in epileptogenesis or not requires
further discussion.
Based on this research, approximately 26 miRNAs exert
a direct or indirect influence in animal experiments of epi-
lepsy diagnosis, being miR-542-3p, miR-362-3p, miR-450-
5p, miR-96, miR-143, miR-23a, miR-155, miR-152, miR-
298, miR-333, miR-330, miR-342-5p, miR-347, miR-34,
miR-294, miR-351, miR-466 family (b-1/b-2/c), miR-675,
miR-758, miR-883, miR-193, miR-134, miR-132, miR-
146a. Other microRNAs may also play a role in epilepsy,
but this remains to be explored.
MicroRNAs in human experiment of DRE
diagnosis
Two studies published in 2012 on miRNA profiles in
TLE revealed a considerable amount of dysregulated
miRNAs in human diseased tissue. Kan et al. [36] fo-
cused on medial temporal lobe epilepsy (mTLE), a sub-
type of TLE caused by hippocampal sclerosis [37]. They
performed genome-wide miRNA profiling in 20 human
hippocampal tissue samples, including both sclerotic and
non-sclerotic. The study also identified 51 strongly regu-
lated miRNAs, wherein 11 miRNAs play essential roles. Of
the 11 miRNAs, 7 were up-regulated- miR-190, miR-20a,
miR-32, miR-374a, miR-26b, miR-193a-3p, miR-92b and 4
were down-regulated - miR-184, miR-138, miR-221, miR-
222. Kan et al. found that miR-92b, miR-637, and miR-665
showed inconsistent localization between being prominent
in the cytoplasm of neurons in autopsy controls and being
in the nucleus of both neurons and astrocytes in mTLE
samples. However, miR-138 expression was limited to the
cytoplasm in mTLE patients. These findings together sug-
gest that the localization of a specific miRNA may have sig-
nificant clinical applications [38]. Consequently, detecting
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the nuclear expression of miR-92a, miR-637 and miR-665
may be a useful method for epilepsy diagnosis. Further-
more, 16 miRNAs involved in epileptogenesis were identi-
fied by summarizing the meaningful results from many
studies, including miRNAs modulating neuronal matur-
ation (miR-137 [39]), neural cell proliferation in cortex
(miR-9 [40], miR-124 [41, 42], miR-137 [40, 43], miR-184
[40, 44, 45] and let-7b [40, 43, 46]), and neural differenti-
ation (miR-153 [47], miR-324 [47], miR-181a [47], miR-34a
[27, 48]). Other miRNAs are reported to be critical in neur-
onal migration (miR-9 [49], miR-134 [23], miR-137 [50]),
neuronal differentiation (miR-125b [51] miR-137 [40]) and
neural inflammation (miR-146a [52]).
Research on epilepsy-related microRNAs in human ex-
periments typically progress slowly because factors key
factors such as drug treatment influence miRNA profiling
results. No clear result has been established on the rela-
tionship between microRNA and intractable epilepsy in
human experiments, leaving a huge development space
for applying microRNAs to potential biomarkers and
therapeutic targets in refractory epilepsy. In this regard, it
is a promising research direction to profile miRNA ex-
pression in both diseased brain tissue and corresponding
plasm samples, and then compare fold changes of miRNA
expressions to those in control groups.
MicroRNAs expression regulation in epilepsy
The mechanism of down-regulation of a series of miRNA
in TLE patients is well understood. McKiernan et al. [45]
profiled miRNA expression in sclerotic hippocampi from
TLE patients and found a significant down-regulation of
37 miRNAs out of the total 380 human miRNAs. In order
to identify the cause of these miRNAs’ collapse, McKier-
nan et al. measured the transcript level of 4 pri-miRNAs
and found no reduction of their levels, but a prominent
decrease in Dicer level was identified. Dicer is an RNase
III essential to the cleavage of pre-miRNA to mature
miRNA. The deletion of Dicer in the neural system typic-
ally leads to neuronal dysfunction, neurodegeneration,
macular degeneration, epilepsy seizure and cognitive defi-
cits [53–57]. The loss of Dicer appears specific to TLE pa-
tients with HS and cause a failure of miRNA biogenesis,
which further gives rise to degenerative changes in cortex
and hippocampal morphology that have been observed in
human epilepsy [54]. Aside from Dicer, other components
of miRNA biogenesis may also play a role in miRNA ex-
pression regulation and may provide potential explanation
for specific miRNA up-regulation. McKiernan et al. [45]
also noticed that Ago2 levels were higher in non-sclerotic
TLE patients. This indicates that epileptic seizures may
up-regulate AGO2, by which miR-451, an up-regulated
miRNA in TLE tissue, could be processed independently
of Dicer [58, 59].
There are two other established miRNA regulators of
note in the neural system and epilepsy: cAMP-response
element binding protein (CREB) and transcription factors.
CREB that regulates miR-132, contributing to the develop-
ment of synaptic network plasticity. Transcription factors
like myocyte enhancing factor 2 (Mef2) up-regulate the
miR379-410 cluster, wherein miR-134 exhibits the essen-
tial role of promoting dendritic outgrowth of hippocampal
neurons by inhibiting translation of translational repressor
Pumilio2 mRNA [60, 61].
Pathogenetic mechanisms of miRNA-mediated
epileptogenesis
Although miRNA is predicted to regulate the expression
of hundreds of proteins involved in wide-ranging bio-
logical processes, the processes regulated by miRNA
may be restricted in epilepsy [23]. Inflammation and
neuron morphology modulation may be two of the most
prominent regulatory roles of miRNA in epileptogenesis
[22]. Similar to miRNA in tumorigenesis, miRNAs exhibit
a dual role in epileptogenesis– neuroprotection or induce
neural cell death. A large number of studies have shown
that the occurrence of epilepsy with nerve cells apoptosis,
Synaptic connections reconstruction, glial fibers cell
hyperplasia, abnormal pathways is closely related to the
formation and inflammatory response [20, 21]. Repeated
seizures can result in hippocampus neuron apoptosis in
brain, the abnormal formation excitatory synapses loop,
and ultimately improve the intractable temporal lobe epi-
lepsy [23, 24]. Thus, miRNAs may be through regulating
nerve cells apoptosis, synaptic contact reconstruction, glial
fiber cell hyperplasia, inflammation involved in the occur-
rence of epilepsy development.
Conclusions and expectation
In the study of human disease, involves only less than
100 kinds of micrornas associated with refractory epi-
lepsy, and collect more meaningful experimental results
including up-regulation of miRNAs : miR-146a,-132,-9,-
99a,-27a,-203,-135a, −4521 [62]; the down-regulation of
miRNAs:miR-30a/b,-138,-324,-330,-187,-194-5p,-301a-
3p,-30b-5p,-342-5p, −4446-3p [63].
Although miRNA research remains in its early stages,
it certainly could have great applications in the molecu-
lar diagnosis of intractable epilepsy. As research into this
area progresses, the miRNA with specificity and sensitiv-
ity will likely be found among numerous miRNAs re-
lated to epilepsy [64]. In time, this will lead to the
development of effective strategies for the early screen-
ing, clinical diagnosis, treament and preventation of re-
fractory epilepsy. The research of miRNA involved in
epilepsy has great application prospect and huge poten-
tial in diagnosis and treatment of intractable epilepsy on
the basis of the molecular biology.
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